Guobang Pharma Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100004NS2
CNY
23.29
0.04 (0.17%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Million
Consolidate Annual Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
Dec'18
Net Sales
5,844.20
5,313.25
5,687.83
4,480.28
4,181.78
3,802.04
3,279.02
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
5,844.20
5,313.25
5,687.83
4,480.28
4,181.78
3,802.04
3,279.02
Raw Material Cost
4,502.84
4,173.63
4,213.02
3,188.78
2,807.40
2,847.30
2,328.05
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
249.50
215.44
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
32.58
27.54
20.08
31.95
47.04
33.74
33.21
Selling and Distribution Expenses
298.88
316.54
315.35
278.89
224.27
213.25
211.62
Other Expenses
16.82
14.25
16.38
11.36
8.39
-16.49
-15.04
Total Expenditure (Excl Depreciation)
5,002.54
4,660.19
4,712.19
3,613.18
3,162.62
3,178.93
2,637.88
Operating Profit (PBDIT) excl Other Income
841.7
653.1
975.6
867.0999999999999
1019.2
623.1
641.1
Other Income
79.76
88.58
103.97
16.82
-12.98
27.52
36.05
Operating Profit (PBDIT)
1,345.55
1,037.16
1,313.74
1,036.35
1,149.64
749.88
745.79
Interest
32.58
27.54
20.08
31.95
47.04
33.74
33.21
Exceptional Items
7.86
10.34
4.51
6.26
0.03
-0.18
-17.74
Gross Profit (PBDT)
1,341.36
1,139.62
1,474.82
1,291.50
1,374.38
954.74
950.97
Depreciation
430.05
322.37
261.79
202.31
157.87
139.03
133.01
Profit Before Tax
890.78
697.59
1,036.38
808.34
944.76
576.92
561.83
Tax
107.39
87.67
115.02
100.55
133.15
81.92
78.37
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
781.60
612.46
920.90
706.03
810.00
314.94
210.87
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
781.60
612.46
920.90
706.03
810.00
314.94
210.87
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
-1.02
-2.49
-0.28
0.20
0.29
179.07
272.59
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
780.58
609.98
920.62
706.23
810.29
494.01
483.46
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
8,047.34
7,432.03
7,155.26
6,346.08
3,274.73
2,616.73
1,248.06
Earnings per share (EPS)
1.4
1.1
1.65
1.26
1.45
0.56
0.38
Diluted Earnings per share
1.4
1.1
1.65
1.26
1.45
0.56
0.38
Operating Profit Margin (Excl OI)
14.3%
11.79%
16.67%
18.24%
24.03%
15.34%
17.59%
Gross Profit Margin
22.6%
19.2%
22.82%
22.56%
26.37%
18.83%
21.19%
PAT Margin
13.37%
11.53%
16.19%
15.76%
19.37%
8.28%
6.43%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Dec 2024 is 9.99% vs -6.58% in Dec 2023

stock-summary

Consolidate Net Profit

YoY Growth in year ended Dec 2024 is 27.97% vs -33.74% in Dec 2023

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Dec 2024 is 33.44% vs -21.59% in Dec 2023

stock-summary

Interest

YoY Growth in year ended Dec 2024 is 18.55% vs 36.82% in Dec 2023

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Dec 2024 has improved from Dec 2023

Compare Annual Results Of Guobang Pharma Ltd. With
Markets Mojo
Figures in Million
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
5,844.20
0
5,844.20
Other Operating Income
0.00
0.00
0.00
Total Operating income
5,844.20
0
5,844.20
Raw Material Cost
4,502.84
0
4,502.84
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
32.58
0
32.58
Selling and Distribution Expenses
298.88
0
298.88
Other Expenses
16.82
0.00
16.82
Total Expenditure (Excl Depreciation)
5,002.54
0
5,002.54
Operating Profit (PBDIT) excl Other Income
841.65
0.00
841.65
Other Income
79.76
0
79.76
Operating Profit (PBDIT)
1,345.55
0
1,345.55
Interest
32.58
0
32.58
Exceptional Items
7.86
0
7.86
Gross Profit (PBDT)
1,341.36
0
1,341.36
Depreciation
430.05
0
430.05
Profit Before Tax
890.78
0
890.78
Tax
107.39
0
107.39
Provisions and contingencies
0
0
0.00
Profit After Tax
781.60
0
781.60
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
781.60
0
781.60
Share in Profit of Associates
0
0
0.00
Minority Interest
-1.02
0
-1.02
Other related items
0.00
0.00
0.00
Consolidated Net Profit
780.58
0
780.58
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
8,047.34
0
8,047.34
Earnings per share (EPS)
1.40
0
1.40
Diluted Earnings per share
1.40
0
1.40
Operating Profit Margin (Excl OI)
14.30%
0%
0.00
14.30%
Gross Profit Margin
22.60%
0%
0.00
22.60%
PAT Margin
13.37%
0%
0.00
13.37%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Annual - Net Sales
Net Sales 584.42 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 9.99% vs -6.58% in Dec 2023

Annual - Consolidate Net Profit
Consolidate Net Profit 78.06 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 27.97% vs -33.74% in Dec 2023

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 126.58 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 33.44% vs -21.59% in Dec 2023

Annual - Interest
Interest 3.26 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 18.55% vs 36.82% in Dec 2023

Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 14.30%
in Dec 2024

Figures in %
stock-summary

YoY Growth in year ended Dec 2024 has improved from Dec 2023